New diabetes drug HMS1005 enters first human tests

NCT ID NCT07568678

Recruiting now Disease control Sponsor: Hua Medicine Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug, HMS1005, in 40 people with type 2 diabetes. The main goal is to check the drug's safety and how the body processes it. Researchers will also look at how it affects blood sugar levels over 24 hours. Participants will receive either the drug or a placebo, and neither they nor the doctors will know who gets what.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HMS1005
What this could lead to: If successful, this could lead to a new oral medication to help control blood sugar in people with type 2 diabetes.
What could go wrong: This is an early phase 1 trial with only 40 participants, so it is primarily checking safety. The drug may not work well or could have side effects. Much more testing is needed before it could become a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Locations

Clinical Pharmacology of Miami
RECRUITING

Miami, Florida, 33172, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.